The Biosimilars Council is hoping the Supreme Court will acknowledge the savings that biosimilar medications can offer to both patients and health systems.
The Biologics Price Competition and Innovation Act was passed by Congress and was drafted in the effort of bringing medicines to patients that are more affordable. The act allowed branded biologics a 12-year period of exclusivity.
A recent Federal Circuit decision, however, would cost patients, private payers and taxpayers billions of dollars in more expensive prescription prices.
Because of the damages that the act would result in, the Association for Accessible Medicines has appealed the ruling to the Supreme Court to make the changes necessary to grant patients access to cheaper medication options.